Durvalumab plus gemcitabine-cisplatin versus S-1 plus gemcitabine-cisplatin in advanced biliary tract cancer: a comparative study

Authors:

Abstract
No abstract available
Funding Information
  • AstraZeneca
  • Guardant Health
  • Ono Pharmaceutical
  • Chugai Pharmaceutical

This publication has 31 references indexed in Scilit: